Engineered TB bacteria could offer new hope for bladder cancer patients
NCT ID NCT06800963
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new version of the BCG therapy, made from a genetically modified bacterium, for people with non-muscle invasive bladder cancer (NMIBC) who have not received BCG before. The treatment is given directly into the bladder through a catheter. The study aims to check if the therapy is safe and to get an early look at how well it works. About 40 participants will be enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Recombinant Mycobacterium (rMBCG), a genetically modified version of the BCG vaccine, given directly into the bladder via a catheter.
What this could lead to
If successful, this could offer a more targeted and potentially safer treatment option for people with early-stage bladder cancer, reducing the need for bladder removal surgery.
What could go wrong
This is an early phase 1/2 trial with only 40 participants, so results are preliminary. The new therapy may cause side effects similar to standard BCG, such as bladder irritation or infection, and may not prove more effective than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMIBC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Arizona Clinical Trials
NOT_YET_RECRUITINGChandler, Arizona, 85224, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Conrad Pearson Clinic
NOT_YET_RECRUITINGGermantown, Tennessee, 38138, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Golden State Urology
RECRUITINGSacramento, California, 95823, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Michigan Institute of Urology & Solaris Health
RECRUITINGTroy, Michigan, 48084, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MidLantic Urology
RECRUITINGCynwyd, Pennsylvania, 19004, United States
Contact Phone: •••-•••-••••
Contact
-
Potamac Urology Center
NOT_YET_RECRUITINGAlexandria, Virginia, 22311, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SUNY Upstate Medical University
NOT_YET_RECRUITINGSyracuse, New York, 13210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Urology Associates, P.C.
RECRUITINGNashville, Tennessee, 37209, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••